Artal Group’s Sage Therapeutics SAGE Stock Holding History

Artal Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500,000	Closed	-$23.5M	–	116
2023 Q2	$23.5M	Sell	500,000 -250,000	-33%	-$12.4M	0.73%	20
2023 Q1	$31.5M	Hold	750,000	–	–	1.87%	16
2022 Q4	$28.6M	Hold	750,000	–	–	1.6%	19
2022 Q3	$29.4M	Buy	750,000 +300,000	+67%	+$11.6M	1.25%	24
2022 Q2	$14.5M	Sell	450,000 -300,000	-40%	-$10.1M	0.78%	31
2022 Q1	$24.8M	Sell	750,000 -250,000	-25%	-$9.4M	1.04%	22
2021 Q4	$42.5M	Hold	1,000,000	–	–	1.15%	25
2021 Q3	$44.3M	Hold	1,000,000	–	–	0.99%	25
2021 Q2	$56.8M	Buy	1,000,000 +350,000	+54%	+$24.7M	1.15%	21
2021 Q1	$48.7M	Buy	650,000 +250,000	+63%	+$20.5M	0.86%	28
2020 Q4	$34.6M	Buy	400,000 +177,700	+80%	+$13.1M	0.74%	36
2020 Q3	$13.6M	Sell	222,300 -11,700	-5%	-$593K	0.33%	66
2020 Q2	$9.73M	Sell	234,000 -116,000	-33%	-$4.21M	0.27%	70
2020 Q1	$10.1M	Buy	350,000 +200,000	+133%	+$11.6M	0.42%	47
2019 Q4	$10.8M	Hold	150,000	–	–	0.42%	42
2019 Q3	$21M	Hold	150,000	–	–	0.84%	21
2019 Q2	$27.5M	Buy	150,000 +25,000	+20%	+$4.27M	1.11%	22
2019 Q1	$19.9M	Buy	125,000 +25,000	+25%	+$3.62M	0.81%	28
2018 Q4	$9.58M	Hold	100,000	–	–	0.35%	47
2018 Q3	$14.1M	Hold	100,000	–	–	0.37%	39
2018 Q2	$15.7M	Hold	100,000	–	–	0.33%	30
2018 Q1	$16.1M	Buy	100,000 +25,000	+33%	+$4.24M	0.2%	39
2017 Q4	$12.4M	Sell	75,000 -75,000	-50%	-$7.27M	0.19%	45
2017 Q3	$9.35M	Buy	150,000 +60,000	+67%	+$4.71M	0.16%	45
2017 Q2	$7.17M	Sell	90,000 -85,000	-49%	-$6.14M	0.13%	43
2017 Q1	$12.4M	Buy	175,000 +25,000	+17%	+$1.46M	0.28%	31
2016 Q4	$7.66M	Sell	150,000 -50,000	-25%	-$2.36M	0.17%	43
2016 Q3	$9.21M	Buy	+200,000	New	+$8.14M	0.18%	38

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's SAGE Position: Q3 2023 in Review

Artal Group sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 500,000 shares — an estimated $23.5M sold.

Artal Group first reported a position in SAGE in Q3 2016 and held it in 28 quarters. The position peaked at $56.8M in Q2 2021. 193 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Artal Group reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Artal Group sold 500,000 Sage Therapeutics shares in Q3 2023, an estimated $23.5M.
Artal Group first reported a position in Sage Therapeutics in Q3 2016 and held it in 28 quarters.
Artal Group's Sage Therapeutics position peaked at $56.8M in Q2 2021.
193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.